Form 4: Brainstorm Cell Therapeutics CEO Acquires Additional Shares

Chaim Lebovits, President and CEO of Brainstorm Cell Therapeutics, recently acquired 66,300 shares of common stock at an average price of $0.3743.

Summary

• On May 7, 2024, Chaim Lebovits, the President and CEO of Brainstorm Cell Therapeutics Inc., acquired 66,300 shares of the company's common stock.
• The shares were purchased at a weighted average price of $0.3743, with individual transaction prices ranging from $0.3738 to $0.3747.
• Following the transaction, Lebovits directly owns 1,059,865 shares of Brainstorm Cell Therapeutics.
• Lebovits may also be deemed the beneficial owner of 2,000,847 indirectly held shares, including 1,933,794 shares owned by ACCBT Corp. and 67,053 shares owned by ACC International Holdings Ltd.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The CEO's purchase of shares could be interpreted as a sign of confidence, but it's a relatively small transaction and doesn't provide definitive insight into the company's overall health.

Positives

• The CEO's purchase of shares may signal confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider trading activity, which is common for publicly traded companies. Investors often monitor such filings for signals about management's confidence in the company's prospects.

Stakeholder Impact

• Shareholders may view the CEO's stock purchase as a positive signal.

Key Dates

Keywords

Brainstorm Cell Therapeutics, BCLI, Chaim Lebovits, Stock Acquisition, SEC Form 4, Beneficial Ownership, Insider Trading